Immunization with Cholesterol-rich Liposomes Induces Anti-cholesterol Antibodies and Reduces Diet-induced Hypercholesterolemia and Plaque Formation
Overview
Pathology
Authors
Affiliations
Immunization of rabbits with a protein-free formulation consisting of liposomes containing 71% cholesterol and lipid A as an adjuvant induced anticholesterol antibodies that caused complement-dependent lysis of liposomes lacking lipid A. The antibodies, immunoglobulin G (IgG) and immunoglobulin M (IgM), also recognized nonoxidized crystalline cholesterol as an antigen by enzyme-linked immunosorbent assay (ELISA). The effects of immunization against cholesterol on elevations in serum cholesterol and development of atherosclerosis were examined in rabbits fed a diet containing 0.5% to 1.0% cholesterol. Although the mean serum cholesterol level, mainly in the form of very-low-density lipoprotein cholesterol, rose as much as 60-fold in the nonimmunized rabbits, the elevation was significantly less--as much as 35% lower--in the immunized rabbits. Elevation of serum cholesterol was accompanied by an apparent drop in the level of antibodies on initiating the diet, followed by a rebound on stopping the diet, thus suggesting that the antibodies were adsorbed to cholesterol that was present in circulating lipoproteins. When lipoprotein fractions--composed of either very-low-density and intermediate-density lipoproteins derived from cholesterol-fed nonimmunized rabbits or human low-density lipoproteins--were tested as capture antigens by solid-phase ELISA, reactivity was observed with IgG and IgM antibodies present in the serum of immunized rabbits. Immunization also resulted in a marked decrease in the risk of developing atherosclerosis. Analysis of aortic atherosclerosis by quantitative histologic examination and fatty streaks by automated morphometric probability-of-occurrence mapping showed diminished atherosclerosis in most areas of the aorta in vaccine recipients. It is proposed that immunization with liposomes containing 71% cholesterol and lipid A can reduce diet-induced hypercholesterolemia and atherosclerosis.
Dobrovolskaia M Front Immunol. 2022; 13:984252.
PMID: 36304452 PMC: 9592561. DOI: 10.3389/fimmu.2022.984252.
Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.
van Alem C, Metselaar J, van Kooten C, Rotmans J Pharmaceutics. 2021; 13(7).
PMID: 34371695 PMC: 8309101. DOI: 10.3390/pharmaceutics13071004.
Immunomodulation of carcinogens-induced steroids-dependent human diseases.
Glushkov A, Polenok E Saudi J Biol Sci. 2019; 26(2):244-251.
PMID: 31485161 PMC: 6717089. DOI: 10.1016/j.sjbs.2017.09.014.
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.
Ilinskaya A, Dobrovolskaia M Toxicol Appl Pharmacol. 2016; 299:70-7.
PMID: 26773813 PMC: 4811736. DOI: 10.1016/j.taap.2016.01.005.
Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.
Chyu K, Shah P Ther Adv Vaccines. 2014; 2(2):56-66.
PMID: 24757525 PMC: 3991155. DOI: 10.1177/2051013613514327.